News 2015

News 2015 

  • Auspherix Appoints Dr. Neil Miller as Chief Scientific Officer

    2 December 2015

    2 December 2015 STEVENAGE, England--( BUSINESS WIRE )--Auspherix Limited (UK), an early stage anti-infectives company, has announced the appointment of Dr. Neil Miller as its Chief Scientific Officer, effective 1 December. As CSO, Dr Miller will take full... read more

  • Construction initiated on Cell Therapy Catapult’s £55 million cell and

    17 November 2015

    17 November 2015 Turf cut on new 7,200m2 facility The Cell Therapy Catapult, the UK organisation dedicated to the growth of the UK cell and gene therapy industry by bridging the gap between scientific research and commercialisation, today announces the official initiation of construction for... read more

  • Puridify completes series A funding for commercialisation of single-us

    22 October 2015

    21 October 2015 – Puridify Limited (“Puridify”), developers of novel bioprocessing purification technologies for industrial biomolecule manufacture, today announced the closing of a £2.2 million Series A funding round. This follow-on investment by existing investors... read more

  • Cell Therapy Catapult appoints main contractor for manufacturing centr

    9 October 2015

    M+W Group to build £55 million large-scale GMP manufacturing centre London, UK, October 9 2015 – The Cell Therapy Catapult has appointed M+W Group to construct its £55 million large-scale GMP manufacturing centre in Stevenage, UK. M+W Group, whose UK headquarters are in... read more

  • Dr Mary Kerr to join NeRRe Therapeutics as CEO

    23 September 2015

    Stevenage, UK, 23 September 2015 - NeRRe Therapeutics Ltd, a clinical stage company developing a portfolio of neurokinin (NK) receptor antagonists, is pleased to announce that Dr Mary Kerr 1 is joining the company as CEO at the beginning of October. Mary has spent the majority of her career on... read more

  • Alliance targets antibiotic-resistant drugs

    16 September 2015

    Domainex in Cambridge and Herts-based Australian biotech Auspherix have extended a collaboration to develop new drugs to tackle the growing threat of resistance to antibiotics. The programme has been extended through to 2017. Since initiating the project in 2014, the companies report significant... read more

  • Ian Tomlinson appointed Independent Chairman of SBC BoardIndustry lead

    2 September 2015

    Stevenage, UK, September 2 2015 – Stevenage Bioscience Catalyst (SBC), the open innovation campus driving collaboration to improve healthcare, has appointed Ian Tomlinson as Independent Chairman. With extensive pharma and biotech experience as Head of Biopharmaceuticals R&D and... read more

  • Cell Therapy Catapult Welcomes Planning Decision for Manufacturing Ce

    25 August 2015

    £55 million large-scale GMP manufacturing centre being built in Stevenage London, UK, 25 August 2015 – The Cell Therapy Catapult has welcomed the decision by Stevenage Borough Council to grant planning permission to construct its £55million large-scale GMP... read more

  • Avacta Raises £22M

    17 July 2015

    Wetherby-based biotechnology business Avacta Group has raised up to £22m by way of a placing with new and existing institutional shareholders. Net proceeds of approximately £21m will be used for infrastructure and in-house development programmes as part of Avacta's strategy to... read more

  • MRC Technology Appoints Technology Transfer Director

    7 July 2015

    Andrew Farquharson has been appointed Director of Technology Transfer at MRC Technology (MRCT) from 1 September. He will head up the team responsible for identifying, protecting and progressing promising life science research to improve human health. Andrew has previously held senior... read more

  • Plasticell appoints Dr Aaron T. T. Chuang as Chief Scientific Officer

    15 June 2015

    New appointment further strengthens thecompany’s expertise in regenerative medicine product development Date: 15 June 2015 Plasticell,the regenerative medicine company utilising its award-winning combinatorial technologies for stem cell research and in developing cell therapies, has... read more

  • MRC Technology and Peptinnovate collaborate on therapeutics for bone

    10 June 2015

    10 June 2015 MRC Technology, an independent medical research charity and Peptinnovate, which is developing first-in-class disease modifying medicines for immuno-inflammatory diseases, are collaborating to assess the therapeutic potential in bone diseases of Peptinnovate’s ... read more

  • Auspherix Raises £6 Million to Progress its Novel Antibiotics and Establishes UK Operations

    3 June 2015

    03 June 2015 In the race to develop new antibiotics with completely new modes of action that might address the growing threat posed by antimicrobial resistance, Auspherix Limited (UK), an early stage anti-infectives company originated in Sydney Australia, has raised £6 million in a... read more

  • Avacta Life Sciences enters into agreement with Moderna

    18 May 2015

    Avacta Group plc ("Avacta" or "the Group") Therapeutic licensing partnership with Moderna Therapeutics, Inc. Avacta Group plc (AIM: AVCT), the global provider of proprietary diagnostic tools, consumables and reagents for life sciences, announces that Avacta Life Sciences has entered into a... read more

  • Cell Therapy Catapult Signs Multiple Collaboration Agreements

    30 March 2015

    30th March 2015 New programmes aim to accelerate regenerative medicine The Cell Therapy Catapult has announced four separate collaborations with multiple-partners to deliver health and wealth to the UK through support from Innovate UK, formerly the Technology Strategy Board. The... read more

  • UCL translational research incubator at Stevenage Bioscience Catalyst

    25 March 2015

    25th March 2015 UCL’s bioscience incubator at the Stevenage Bioscience Catalyst (SBC) has now reached capacity following the migration of two further research projects to the facility from the university’s central London campus. The new research projects have been strategically... read more

  • A tribute to Dr Allan Baxter 1950-2015

    17 February 2015

    Dr Allan Baxter, who died at the end of January, played a major role at Stevenage Bioscience Catalyst right from its inception. With leadership at the Board level as our first Chairman, guidance and participation in our activities, and enthusiasm for our tenants and their work, he brought his... read more

  • NanoScientium delivers business-critical support to VaccineTab

    9 February 2015

    February 2015 NanoScientium announces the completion of a project with VaccineTab, a start-up from Queen’s University Belfast. VaccineTab, led by Dr Vicky Kett, has a proprietary vaccine delivery technology which is thermally stable, therefore reducing the need for cold chain storage and... read more

  • Plasticell wins Innovate UK funding for £1.6million cord blood stem ce

    9 February 2015

    5th February 2015 Innovate UK will provide a grant of approximately £1.3 million to a research consortium led by Plasticell for a project entitled ‘Ex-vivo expansion of cordblood and bone marrow stem cells”. The consortium includes the University of Oxford and the Cell Therapy... read more

  • Six new approaches to fighting neurodegeneration to be funded in SBC's

    24 January 2015

    Six new approaches to fighting neurodegeneration to be funded in SBC's OI challenge Diverse players collaborate on first step in plan to tackle disorder via open innovation Stevenage UK, January 21 2015 – Stevenage Bioscience Catalyst (SBC), the UK’s first open innovation... read more

  • Stevenage Bioscience Catalyst Chair steps down due to illness

    12 January 2015

    Allan Baxter has stepped down as Chair of Stevenage Bioscience Catalyst (SBC) due to an unexpected deterioration in a long-standing health condition. John Cooper, the Wellcome Trust’s nominated Director of SBC has taken over as Interim Chair of the company with immediate effect. Allan had... read more

Funding Partners: